- Home
- DUO vs ALGS Comparison
DUO vs ALGS Comparison
Compare DUO & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DUO | ALGS |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.5M | 34.6M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DUO | ALGS |
|---|---|---|
| Price | $0.62 | $5.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 56.4K | ★ 105.2K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $3.98 |
| 52 Week High | $5.34 | $13.69 |
Technical Indicators
Market Signals| Indicator | DUO | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 56.92 |
| Support Level | $0.56 | $4.80 |
| Resistance Level | $0.70 | $5.94 |
| Average True Range (ATR) | 0.06 | 0.50 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 33.15 | 84.07 |
Price Performance
Historical ComparisonAbout DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China. All revenues of the Group are derived from the PRC.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.